Mode
Text Size
Log in / Sign up
N/A N=32 Randomized Quadruple-blind Treatment

Transcranial Alternating Current Stimulation for Major Depressive Disorder

Major Depressive Disorder · MDD

Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Aug 2018
Primary outcome: Primary: Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Score — -13.60; -8.82; -8.27 units on a scale — p=>0.10

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
tACS (alpha) (Device); tACS (gamma) (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of North Carolina, Chapel Hill
Primary completion
Jun 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Score
-13.60; -8.82; -8.27 >0.10
SECONDARY
Change in Alpha Oscillation Power From Resting State EEG Recordings on the First and Last Day of Stimulation
-1.75; 0.53; 0.24; -1.23; 0.12; -0.02 <0.05 sig
SECONDARY
Change in Alpha Oscillation Power From Resting State EEG Recordings on the First of Stimulation to 4 Weeks After Completion of Intervention
-0.42; 0.09; 0.55; -0.57; 0.00; 0.41 >0.10

Summary

Investigating the effects of non-invasive transcranial alternating current stimulation (tACS) on patients with Major Depressive Disorder (MDD).

Eligibility Criteria

Inclusion Criteria

  • Male or female, 18-65 years old
  • Diagnostic and Statistical Manual of Mental Disorder, 4th edition (DSM-IV) diagnosis of MDD; unipolar, non-psychotic
  • Hamilton Depression Rating Scale score >8
  • Capacity to understand all relevant risks and potential benefits of the study (informed consent)
  • Meet criteria for low suicide risk
  • Willing to comply with all study procedures and be available to do so for the duration of the study
  • Women of reproductive potential must use highly effective contraception

Exclusion Criteria

  • DSM-IV diagnosis of alcohol of substance abuse (other than nicotine) within the last month or a DSM-IV diagnosis of alcohol or substance dependence (other than nicotine) within the last 6 months
  • Current use of benzodiazepines or anti-epileptic drugs
  • Current axis I mood, or psychotic disorder other than major depressive disorder
  • Lifetime comorbid psychiatric bipolar or psychotic disorder
  • Eating disorder (current or within the past 6 months)
  • Obsessive-compulsive disorder (lifetime)
  • Post traumatic stress disorder (PTSD; current or within the last 6 months)
  • Attention Deficit Hyperactivity Disorder (ADHD; currently under treatment)
  • Anything that, in the opinion of the investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the study
  • Neurological disorders, including but not limited to history of seizures (except childhood febrile seizures and ECT induced seizures), dementia, history of stroke, Parkinson's disease, multiple sclerosis, cerebral aneurism
  • Medical or neurological illness (unstable cardiac disease, AIDS, malignancy, liver or renal impairment) or treatment for a medical disorder that could interfere with study participation
  • History of traumatic brain injury, reoccurring seizures or later cognitive rehabilitation, or causing cognitive sequelae
  • Prior brain surgery
  • Any brain devices/implants, including cochlear implants and aneurysm clips
  • Co-morbid neurological condition (i.e. seizure disorder, brain tumor)
  • Non English speakers
  • Pregnancy, nursing, or if female and fertile, unwilling to use appropriate birth control measures during study participation
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02339285). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search